Experimental Dermatology最新文献

{"title":"USP11 Overexpression Ameliorates Vitiligo by Suppressing Oxidative Stress-Induced Melanocyte Damage Through Deubiquitination Modification of SIRT3.","authors":"Xiaojuan Nie, Yuanyuan Li, Ling Yuan, Mingxia Sun","doi":"10.1111/exd.70255","DOIUrl":"https://doi.org/10.1111/exd.70255","url":null,"abstract":"<p><p>Oxidative stress is identified as a potential factor in vitiligo pathogenesis. We aimed here to evaluate whether USP11 regulates the oxidative stress of melanocytes in vitiligo. Human melanocyte PIG1 cells were induced with 1 mM H₂O₂ and pre-infected with lentiviruses for genetic intervention. The dorsal skin of C57BL/6J mice was applied with 5% H₂O₂, and genetic intervention was elicited through adenoviruses. USP11, SIRT3, and TRIM28 were reduced in melanocytes (Melan-A positive) from vitiligo mouse skin tissues and in the H₂O₂-induced PIG1 cells. TRIM28 transcriptionally activated USP11 to promote deubiquitination of SIRT3. H₂O₂ decreased viability and melanin and tyrosinase contents and increased apoptosis and oxidative stress in PIG1 cells. H₂O₂ induced severe depigmentation of the dorsal skin in mice, reduced melanin deposition in hair follicles, loss of melanocytes, and increased oxidative stress. Overexpression of either USP11 or TRIM28 inhibited H₂O₂-induced melanocyte damage and vitiligo, while combined knockdown of SIRT3 or USP11 reversed the effects of USP11 or TRIM28 overexpression. These findings suggest that TRIM28 exerts its effect by reducing oxidative stress in melanocytes through USP11-mediated SIRT3 deubiquitination. This observation provides a mechanistic insight that could inform future therapeutic exploration in vitiligo. Graphical abstract text. The diagram. TRIM28 inhibits oxidative stress damage in melanocytes and alleviates vitiligo by transcriptionally upregulating USP11 and promoting deubiquitination modification of SIRT3.</p>","PeriodicalId":12243,"journal":{"name":"Experimental Dermatology","volume":"35 5","pages":"e70255"},"PeriodicalIF":3.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Efficacy and Safety of Intramuscular Injections of Autologous Total IgG in Patients With Chronic Spontaneous Urticaria: An Open-Label Prospective Pilot Trial","authors":"Young-Min Ye,&nbsp;Myung-Eun Kim,&nbsp;Byul Kwon,&nbsp;Dong-Ho Nahm","doi":"10.1111/exd.70249","DOIUrl":"10.1111/exd.70249","url":null,"abstract":"<p>Chronic spontaneous urticaria (CSU) remains challenging to manage in patients who do not respond adequately to antihistamines or currently available immunomodulatory therapies. Intramuscular injection of autologous total IgG (autologous immunoglobulin therapy: AIGT) has demonstrated clinical efficacy, safety and immunomodulatory effects in patients with moderate-to-severe atopic dermatitis in a randomized placebo-controlled clinical trial. However, the clinical usefulness of AIGT in patients with CSU has not been evaluated. We conducted a prospective open-label pilot study to assess the efficacy and safety of AIGT in antihistamine-refractory CSU. Fifteen adults with CSU received nine weekly intramuscular injections of 100 mg autologous IgG from Week 0 through Week 8 (inclusive). The primary outcome was the change in Urticaria Activity Score over 7 days (UAS7) at Week 12 from baseline. Secondary outcomes included the Urticaria Control Test (UCT), chronic urticaria-specific quality of life (CU-QoL) scores and patient-reported disease burden using a visual analogue scale (VAS). The median change in UAS7 at Week 12 from baseline was −13.0 (<i>p</i> &lt; 0.001). Significant improvements in UCT, CU-QoL and VAS were also observed at Week 12 from baseline (<i>p</i> &lt; 0.05). In longitudinal analyses, improvements in symptom burden and quality of life were detectable from Week 4 and were maintained through Week 24. Serum total IgG increased by a median of +68.0 mg/dL from baseline to Week 12 (<i>p</i> &lt; 0.05). No serious adverse events occurred. In conclusion, AIGT improved disease activity, urticaria control, quality of life and patient-reported burden in patients with antihistamine-refractory CSU. Further studies are needed to evaluate the clinical usefulness of AIGT in CSU.</p>","PeriodicalId":12243,"journal":{"name":"Experimental Dermatology","volume":"35 4","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/exd.70249","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioelectric Profiling of Atopic Dermatitis: From Molecular Barrier Defects to Closed-Loop Theranostic Strategies","authors":"Yaya Du,&nbsp;Mengya Zhao,&nbsp;Zhuo Zuo,&nbsp;Yulong Sun","doi":"10.1111/exd.70250","DOIUrl":"10.1111/exd.70250","url":null,"abstract":"<p>Atopic dermatitis (AD) is a chronic inflammatory dermatosis characterised by skin barrier disruption and immune dysregulation. Current clinical scoring systems (e.g., SCORAD) often fail to quantify subclinical pathophysiology or characterise the biopharmaceutical interface. This review synthesises the ‘bioelectric profile’ of AD, integrating electrical impedance spectroscopy (EIS) and current perception threshold (CPT) to construct a precision phenotyping framework. Evidence indicates that EIS non-invasively quantifies barrier integrity, with specific parameters (e.g., EIS^diff) that correlate positively with terminal differentiation proteins such as filaggrin, serving as a surrogate marker of molecular permeability. Concurrently, neuroselective CPT assessment reveals abnormal C-fibre sensitisation in non-lesional skin, distinguishing extrinsic from intrinsic AD phenotypes. Furthermore, we explore reciprocal interactions between bioelectric parameters, Th2/Th22 cytokines (e.g., IL-31, IL-13) and the microbiome. Finally, we discuss translating these signatures into closed-loop theranostic strategies for feedback-controlled drug delivery. This bioelectric panorama provides a unique biophysical perspective on AD pathogenesis and a theoretical foundation for future precision medicine.</p>","PeriodicalId":12243,"journal":{"name":"Experimental Dermatology","volume":"35 4","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/exd.70250","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147671773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biologic Efficacy by BMI in Moderate-To-Severe Psoriasis: A Real-World Cohort Study","authors":"Xin Shen,&nbsp;Fan Wang,&nbsp;Rui Wang,&nbsp;Huan Liu,&nbsp;Erle Dang,&nbsp;Chen Yu,&nbsp;Gang Wang","doi":"10.1111/exd.70252","DOIUrl":"10.1111/exd.70252","url":null,"abstract":"<div>\u0000 \u0000 <p>Obesity reduces response to biologic therapy in psoriasis, but comparative evidence across drug classes in Chinese patients is limited. A real-world cohort of 891 adults with moderate-to-severe psoriasis initiating biologics between 2020 and 2025 was divided by baseline BMI (&lt; 24 vs. ≥ 24 kg/m²). PASI90 achievement at 2, 4, 6 and 12 months and drug survival were compared amongst IL-17, IL-23 and TNF-α inhibitors. Amongst IL-17 users, PASI90 rates in the non-overweight group were consistently higher at 4, 6 and 12 months (all <i>p</i> &lt; 0.05), whereas no BMI-related differences were seen with TNF-α or IL-23 blockade. Within the non-overweight stratum, IL-17 and IL-23 agents outperformed TNF-α inhibitors at month 6 and yielded fewer switches (<i>p</i> &lt; 0.05). In the overweight/obese stratum, IL-23 blockade achieved the highest PASI90 rates and longest drug survival versus both IL-17 and TNF-α inhibitors (<i>p</i> &lt; 0.05). In this real-world cohort of Chinese psoriasis patients, BMI was observed to correlate with biologic effectiveness in a drug-specific manner. Our findings suggest that whilst IL-17 or IL-23 inhibitors showed favourable outcomes for non-overweight individuals, IL-23 blockade may be associated with a more sustained response in those categorised as overweight or obese.</p>\u0000 </div>","PeriodicalId":12243,"journal":{"name":"Experimental Dermatology","volume":"35 4","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147671770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DUSP6 Regulates Skin Inflammation, Parakeratosis and Disease Severity in a Murine Model of Psoriasis","authors":"Teresina Laragione,&nbsp;Carolyn Harris,&nbsp;Robert Phelps,&nbsp;Percio S. Gulko","doi":"10.1111/exd.70245","DOIUrl":"10.1111/exd.70245","url":null,"abstract":"<div>\u0000 \u0000 <p>Psoriasis is a chronic inflammatory skin disease characterised by keratinocyte hyperproliferation and immune cell infiltration driven by cytokines such as IL-17A. The dual-specificity phosphatase 6 (DUSP6) is a negative regulator of MAPK signalling and was previously reported to be a key mediator of arthritis severity. Here, we examine the role of DUSP6 in a mouse model of psoriasis. Psoriasis was studied in the imiquimod-induced model (IMQ). The skin of DUSP6+/+ and DUSP6−/− mice was treated with IMQ cream. Disease severity was assessed using well-established clinical and histologic systems. Skin inflammatory genes were quantified by qPCR.DUSP6−/− mice exhibited significantly reduced skin inflammation with lower PASI clinical scores (mean DUSP6−/− 1.8 and DUSP6+/+ 8.4; <i>p</i> &lt; 0.0001). Histologic scores for epidermal thickening, parakeratosis and immune cell infiltration were decreased in the DUSP6−/− mice (<i>p</i> &lt; 0.0005), and mRNA levels of IL1β, IL17A and STAT3 were lower in DUSP6−/− skin (<i>p</i> ≤ 0.05) compared with DUSP6+/+. In conclusion, DUSP6 is required for the development of psoriasis-like skin inflammation in mice. In the absence of DUSP6, mice were protected and had significantly lower levels of pathogenic genes, suggesting a new and central role for DUSP6 in skin inflammation and a potential therapeutic target in psoriasis.</p>\u0000 </div>","PeriodicalId":12243,"journal":{"name":"Experimental Dermatology","volume":"35 4","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Intervention with Calcineurin Inhibitors in Paediatric Segmental Vitiligo: A Retrospective Case Series","authors":"Alessia Paganelli,&nbsp;Giovanni Luca Scaglione,&nbsp;Vito Giuseppe Di Lernia,&nbsp;Iria Neri,&nbsp;Alessandra Corrente,&nbsp;Mauro Picardo","doi":"10.1111/exd.70248","DOIUrl":"10.1111/exd.70248","url":null,"abstract":"<div>\u0000 \u0000 <p>Segmental vitiligo (SV) is a distinct subtype of vitiligo characterized by an early onset, unilateral distribution, and rapid stabilization. Although traditionally considered neurogenic in origin, recent evidence suggests an immune-mediated pathomechanism. However, the molecular mechanisms underlying SV remain poorly characterized, and therapeutic options are limited. Topical calcineurin inhibitors (TCI) are widely used in immune-mediated dermatoses, but clinical data supporting their use in SV are scarce. We conducted a retrospective observational study of paediatric patients with SV treated with TCI, recording demographics, disease duration and 3-month clinical response. In parallel, selected public transcriptomic datasets were re-analysed to examine enrichment of TCR/Ca2 + −calcineurin/NFAT-related pathways as supportive mechanistic context. Five of eight patients (62.5%) achieved significant repigmentation (VNS ≥ 4) after 12 weeks, with shorter disease duration correlating with better outcomes (<i>p</i> = 0.0002451). Early intervention determined good clinical response even in cases with leukotrichia, and no adverse effects were observed. Transcriptomic re-analysis provided supportive, descriptive signals consistent with activation of T-cell signalling and Ca2 + −calcineurin/NFAT pathways in SV blood, while proxy datasets from non-segmental vitiligo skin did not show similar enrichment. Overall, in this small retrospective paediatric case series, early use of topical calcineurin inhibitors was associated with favourable clinical outcomes in SV and demonstrated a good safety profile. Larger, prospective studies are warranted to confirm these preliminary findings and refine therapeutic strategies.</p>\u0000 </div>","PeriodicalId":12243,"journal":{"name":"Experimental Dermatology","volume":"35 4","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147616081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential Tumour Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK) Associations in Pemphigus and Bullous Pemphigoid.","authors":"Shiran Kang, Jialu Zhao, Meixuan Li, Yumin Xia, Yale Liu","doi":"10.1111/exd.70251","DOIUrl":"https://doi.org/10.1111/exd.70251","url":null,"abstract":"","PeriodicalId":12243,"journal":{"name":"Experimental Dermatology","volume":"35 4","pages":"e70251"},"PeriodicalIF":3.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EXPRESSION OF CONCERN: Decreased Presence of Langerhans Cells Is a Critical Determinant for Indian Post Kala-Azar Dermal Leishmaniasis","authors":"","doi":"10.1111/exd.70243","DOIUrl":"10.1111/exd.70243","url":null,"abstract":"<p>\u0000 <b>EXPRESSION OF CONCERN</b>: <span>S. Mukherjee</span>, <span>D. Mukhopadhyay</span>, <span>C. Braun</span>, <span>J. N. Barbhuiya</span>, <span>N. K. Das</span>, <span>U. Chatterjee</span>, <span>E. Stebut</span>, and <span>M. Chatterjee</span>, “Decreased Presence of Langerhans Cells Is a Critical Determinant for Indian Post Kala-Azar Dermal Leishmaniasis,” <i>Experimental Dermatology</i> <span>24</span>, no. <span>3</span> (<span>2015</span>): <span>232</span>–<span>234</span>, https://doi.org/10.1111/exd.12635.\u0000 </p><p>This Expression of Concern is for the above article, published online on 10 January 2015 in Wiley Online Library (wileyonlinelibrary.com), and has been issued by agreement between the journal Editor-in-Chief, Dong Hun Lee; and John Wiley &amp; Sons Ltd. Concerns were raised by a third party that the IL-10 (Pre1-Post3) band, beta-actin (N1-N3) band, and beta-actin (Pre1-Post3) band in Figure 2F of this article had been duplicated in an article published in the same year by some of the same authors [Mukhopadhyay et al. 2015 (https://doi.org/10.1371/journal.pntd.0004145)]. Both articles describe different experimental conditions. Further investigation by the publisher found that these same bands had been duplicated in another article by some of the same authors [Mukherjee et al. 2019 (https://doi.org/10.1038/s41598-018-37144-y)] and that the representative image for Macular lesion in Figure 1A had been reused in a different article by some of the same authors [Roy et al. 2024 (https://doi.org/10.4269/ajtmh.23-0197)] without acknowledgement.</p><p>The authors responded to an inquiry by the publisher and stated that the beta-actin bands shared between both 2015 articles were performed on the same set of samples but acknowledged that the IL-10 image in the earlier article had been duplicated and represented as VDR in Mukhopadhyay et al. 2015 and PD-1 in Mukherjee et al. 2019. The authors also confirmed that they had not added acknowledgement that the patient reported in this article was followed up in Roy et al. 2024. Original data were no longer available for the experiments reported in this article.</p><p>The editors and publisher have determined that the explanations provided by the authors were not sufficient to account for apparent data re-use and presentation of the data as different samples. Furthermore, the representation of these samples as different within the same year of publication casts doubt on the accuracy of their presentation in this article. The Expression of Concern has been agreed to in order to inform and alert readers to the results of the investigation and to the remaining concerns of data presented in Figure 2F. The authors were informed about the Expression of Concern.</p>","PeriodicalId":12243,"journal":{"name":"Experimental Dermatology","volume":"35 4","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/exd.70243","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147581169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Proteomic Profiling Uncovers Dysregulated Keratinisation and Immune-Related Pathways in Hidradenitis Suppurativa","authors":"Chiara Moltrasio,&nbsp;Sara Roncarà,&nbsp;Blendi Ura,&nbsp;Elena Maria Nardacchione,&nbsp;Eduardo Sommella,&nbsp;Ronald Moura,&nbsp;Federica Derlino,&nbsp;Angelo Valerio Marzano,&nbsp;Sergio Crovella,&nbsp;Paola Maura Tricarico","doi":"10.1111/exd.70244","DOIUrl":"10.1111/exd.70244","url":null,"abstract":"<p>Hidradenitis suppurativa (HS) is an autoinflammatory keratinisation disease affecting the pilosebaceous unit and hallmarked by a complex and multifactorial pathogenesis. Although genomic and transcriptomic investigations have substantially advanced our understanding of key mechanisms underlying HS pathogenesis, proteomic studies remain limited, despite the significant potential of serum proteomics to identify molecular signatures reflecting both cutaneous and systemic inflammatory activity. This exploratory study presents a serum proteomic analysis of patients with moderate-to-severe HS, identifying 306 differentially abundant proteins out of 3153 profiled (FDR <i>q</i> &lt; 0.10). Sensitivity analysis at <i>q</i> &lt; 0.05 (194 proteins) confirmed a robust inflammatory signature, while the FDR <i>q</i> &lt; 0.10 threshold was necessary to preserve markers of epidermal homeostasis, which are inherently diluted in systemic circulation. Enrichment analyses revealed dysregulated pathways related to keratinisation, epidermal differentiation and extracellular matrix (ECM) remodelling, indicating impaired skin barrier function. Concurrent higher abundance of immune-related pathways, including defence response to bacterium, complement activation and neutrophil degranulation, suggest systemic inflammation potentially linked to microbial dysbiosis. These findings suggest the dual role of epithelial dysfunction and autoinflammation in HS pathogenesis. Integration of proteomic data with genomic and transcriptomic findings underscores the value of multi-omics approaches in guiding targeted therapeutic development.</p>","PeriodicalId":12243,"journal":{"name":"Experimental Dermatology","volume":"35 4","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13023024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147527983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Topical Delgocitinib for Chronic Hand Eczema: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","authors":"Rafaela de Moraes-Souza,&nbsp;Maria Júlia Pilau Bornia,&nbsp;Regina Chahine Chater,&nbsp;Francesco Piscazzi,&nbsp;Matheus Barros de Albuquerque,&nbsp;Yasmin Mesquita,&nbsp;Izadora Lapenda,&nbsp;Guillermo Servera-Negre,&nbsp;Natalia Hernández-Cano,&nbsp;Rubiana Sarto,&nbsp;Pedro Herranz-Pinto","doi":"10.1111/exd.70242","DOIUrl":"10.1111/exd.70242","url":null,"abstract":"<p>Chronic hand eczema (CHE) is associated with substantial functional impairment and reduced quality of life. Delgocitinib, a pan-Janus kinase (JAK) inhibitor, has emerged as a promising topical treatment for CHE. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to assess the efficacy and safety of topical delgocitinib 20–30 mg/g compared with vehicle in patients with CHE. PubMed, Embase, Cochrane Library, ClinicalTrials.gov, EU CTR, and WHO ICTRP were searched up to 15 February 2026. The primary outcome was treatment success at week 16, defined as clear or almost clear skin with a ≥ 2-point improvement on the Investigator's or Physician's Global Assessment (IGA/PGA). Secondary outcomes included treatment success at weeks 4 and 8, changes in Hand Eczema Symptom Diary (HESD) itch and pain scores, and safety outcomes. Relative risks (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were calculated using random-effects models. Three publications reporting four RCTs involving 1154 patients were included, with 752 receiving delgocitinib and 402 receiving vehicle. At week 16, treatment success was significantly higher with delgocitinib (RR 3.17; 95% CI 1.78–5.65; <i>p</i> &lt; 0.01), corresponding to an absolute risk difference of 16.9% and a number needed to treat (NNT) of 6 (95% CI 3–16). Similar results at weeks 4 and 8. Delgocitinib also led to significantly greater improvements in HESD itch and pain scores. No significant differences were found in overall adverse events (AEs), treatment-related AEs, or serious AEs. Discontinuation due to AEs was lower in the delgocitinib group. Delgocitinib 20–30 mg/g demonstrated greater efficacy than vehicle and a favourable safety profile, supporting its use as a topical treatment for CHE.</p>","PeriodicalId":12243,"journal":{"name":"Experimental Dermatology","volume":"35 4","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13023025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147527978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}